FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200569722> ?p ?o ?g. }

• W4200569722 endingPage "S725" @default.
• W4200569722 startingPage "S725" @default.
• W4200569722 abstract "Abstract Background Ceftolozane/tazobactam (C/T) is an antipseudomonal cephalosporin combined with a β-lactamase inhibitor approved by FDA and EMA for complicated urinary tract (cUTI) and complicated intraabdominal infections (cIAI), as well as hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) in patients ≥18 years. Clinical trials studying the use of C/T for pediatric patients with cUTI and cIAI are completed, and HABP/VABP pediatric studies are underway. We evaluated the antimicrobial activity of C/T against gram-negative isolates collected from patients ≤17 years in the United States (US) as part of the global SMART surveillance program. Methods In 2017-2019, 27 US clinical labs each collected up to 250 consecutive gram-negative pathogens per year. A total of 1336 isolates were collected from pediatric patients. MICs were determined using CLSI broth microdilution and breakpoints. C/T-nonsusceptible Enterobacterales (Ebact) and P. aeruginosa were screened for genes encoding β-lactamases. Results Among the 944 collected Ebact and 220 P. aeruginosa isolates, 40.7% and 76.4%, respectively, were collected from patients with respiratory tract infections, 37.0% and 10.0% from UTI, 13.7% and 8.2% from IAI, and 8.3% and 5.0% from bloodstream infections. The table shows antimicrobial susceptibility of Ebact, P. aeruginosa, and select phenotypes. C/T was active against 98% of Ebact, including 50 of 51 and 12 of 13 ESBL-non-CRE phenotype E. coli and K. pneumoniae, respectively. Among P. aeruginosa, C/T was active against 95% of isolates, 9-21 percentage points higher than the comparator β-lactams, and it maintained activity against 71-75% of P. aeruginosa isolates nonsusceptible to commonly used β-lactams. Among the 21 C/T-nonsusceptible Ebact, 2 isolates carried KPC and ESBL and 3 isolates carried only ESBL; in 16 isolates no β-lactamases were detected, of which 15 were species with intrinsic AmpC. Among 12 C/T-nonsusceptible P. aeruginosa, no acquired β-lactamases were detected, likely indicating chromosomally-mediated resistance mechanisms. Results Table Conclusion C/T could be a potential new treatment option for US pediatric patients with infections caused by Ebact and P. aeruginosa, including resistant phenotypes. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Meredith Hackel, PhD MPH, IHMA (Employee)Pfizer, Inc. (Independent Contractor) C. Andrew DeRyke, PharmD, Merck & Co., Inc. (Employee, Shareholder) Kelly Harris, PharmD, BCPS, Merck & Co. Inc (Employee) Katherine Young, MS, Merck (Employee) Mary Motyl, PhD, Merck & Co., Inc. (Employee, Shareholder) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
• W4200569722 created "2021-12-31" @default.
• W4200569722 creator A5010520517 @default.
• W4200569722 creator A5017159626 @default.
• W4200569722 creator A5020290756 @default.
• W4200569722 creator A5037643218 @default.
• W4200569722 creator A5038009031 @default.
• W4200569722 creator A5042149117 @default.
• W4200569722 creator A5089366807 @default.
• W4200569722 date "2021-11-01" @default.
• W4200569722 modified "2023-10-17" @default.
• W4200569722 title "1273. Activity of Ceftolozane/Tazobactam and Comparators Against Enterobacterales and P. aeruginosa Isolates from Pediatric Patients—SMART United States 2017-2019" @default.
• W4200569722 doi "https://doi.org/10.1093/ofid/ofab466.1465" @default.
• W4200569722 hasPublicationYear "2021" @default.
• W4200569722 type Work @default.
• W4200569722 citedByCount "0" @default.
• W4200569722 crossrefType "journal-article" @default.
• W4200569722 hasAuthorship W4200569722A5010520517 @default.
• W4200569722 hasAuthorship W4200569722A5017159626 @default.
• W4200569722 hasAuthorship W4200569722A5020290756 @default.
• W4200569722 hasAuthorship W4200569722A5037643218 @default.
• W4200569722 hasAuthorship W4200569722A5038009031 @default.
• W4200569722 hasAuthorship W4200569722A5042149117 @default.
• W4200569722 hasAuthorship W4200569722A5089366807 @default.
• W4200569722 hasBestOaLocation W42005697221 @default.
• W4200569722 hasConcept C126322002 @default.
• W4200569722 hasConcept C176947019 @default.
• W4200569722 hasConcept C2777637488 @default.
• W4200569722 hasConcept C2777914695 @default.
• W4200569722 hasConcept C2780950330 @default.
• W4200569722 hasConcept C4937899 @default.
• W4200569722 hasConcept C501593827 @default.
• W4200569722 hasConcept C523546767 @default.
• W4200569722 hasConcept C54355233 @default.
• W4200569722 hasConcept C64778159 @default.
• W4200569722 hasConcept C71924100 @default.
• W4200569722 hasConcept C86803240 @default.
• W4200569722 hasConcept C89423630 @default.
• W4200569722 hasConceptScore W4200569722C126322002 @default.
• W4200569722 hasConceptScore W4200569722C176947019 @default.
• W4200569722 hasConceptScore W4200569722C2777637488 @default.
• W4200569722 hasConceptScore W4200569722C2777914695 @default.
• W4200569722 hasConceptScore W4200569722C2780950330 @default.
• W4200569722 hasConceptScore W4200569722C4937899 @default.
• W4200569722 hasConceptScore W4200569722C501593827 @default.
• W4200569722 hasConceptScore W4200569722C523546767 @default.
• W4200569722 hasConceptScore W4200569722C54355233 @default.
• W4200569722 hasConceptScore W4200569722C64778159 @default.
• W4200569722 hasConceptScore W4200569722C71924100 @default.
• W4200569722 hasConceptScore W4200569722C86803240 @default.
• W4200569722 hasConceptScore W4200569722C89423630 @default.
• W4200569722 hasIssue "Supplement_1" @default.
• W4200569722 hasLocation W42005697221 @default.
• W4200569722 hasLocation W42005697222 @default.
• W4200569722 hasOpenAccess W4200569722 @default.
• W4200569722 hasPrimaryLocation W42005697221 @default.
• W4200569722 hasRelatedWork W2030310773 @default.
• W4200569722 hasRelatedWork W2077951950 @default.
• W4200569722 hasRelatedWork W2151828834 @default.
• W4200569722 hasRelatedWork W2163897874 @default.
• W4200569722 hasRelatedWork W2327841404 @default.
• W4200569722 hasRelatedWork W2753184995 @default.
• W4200569722 hasRelatedWork W2948070210 @default.
• W4200569722 hasRelatedWork W2964010063 @default.
• W4200569722 hasRelatedWork W2986376659 @default.
• W4200569722 hasRelatedWork W3046721888 @default.
• W4200569722 hasVolume "8" @default.
• W4200569722 isParatext "false" @default.
• W4200569722 isRetracted "false" @default.
• W4200569722 workType "article" @default.